Center-Authored Papers

Filters: Author is Kaewkungwal, Jaranit  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zolla-Pazner S, DeCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA et al..  2014.  Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection.. PloS one. 9(2):e87572. Abstract
Zolla-Pazner S, Edlefsen PT, Rolland M, Kong X-P, DeCamp A, Gottardo R, Williams C, Tovanabutra S, Sharpe-Cohen S, Mullins JI et al..  2014.  Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses.. EBioMedicine. 1(1):37-45. Abstract
Y
Yates NL, Liao H-X, Fong Y, DeCamp A, Vandergrift NA, Williams WT, Alam MS, Ferrari G, Yang Z-Y, Seaton KE et al..  2014.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination.. Science translational medicine. 6(228):228ra39. Abstract
W
Wang Y, Whittall T, Neil S, Britton G, Mistry M, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Yu X et al..  2017.  A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection.. Scientific reports. 7(1):1057. Abstract
V
Vasan S, Rerks-Ngarm S, Gilbert P, Haynes B, Nitayapan S, Pitisuttihum P, Kaewkungwal J, Excler J-L, Robb M, Michael N et al..  2015.  Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection.. Human vaccines & immunotherapeutics. 11(4):1036-7.
T
Tomaras GD, Ferrari G, Shen X, Alam MS, Liao H-X, Pollara J, Bonsignori M, Moody AM, Fong Y, Chen X et al..  2013.  Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.. Proceedings of the National Academy of Sciences of the United States of America. 110(22):9019-24. Abstract
R
Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M et al..  2012.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.. The Lancet infectious diseases. 12(7):531-7. Abstract
P
Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W et al..  2015.  HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.. Science translational medicine. 7(296):296ra112. Abstract
Perez LG, Martinez DR, Decamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H et al..  2017.  V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.. PloS one. 12(7):e0180720. Abstract
M
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E et al..  2012.  Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials.. The Journal of infectious diseases. 206(3):431-41. Abstract
L
Liu P, Yates NL, Shen X, Bonsignori M, Moody AM, Liao H-X, Fong Y, Alam MS, Overman GR, Denny T et al..  2013.  Infectious Virion Capture by HIV-1 gp120 Specific IgG from RV144 Vaccinees.. Journal of virology. Abstract
Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart P-A et al..  2015.  COMPASS identifies T-cell subsets correlated with clinical outcomes.. Nature biotechnology. 33(6):610-6. Abstract
K
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X et al..  2012.  The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120.. AIDS research and human retroviruses. 28(11):1444-57. Abstract
J
Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP et al..  2015.  HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.. Nature medicine. Abstract
H
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam MS, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al..  2012.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86. Abstract
G
Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L et al..  2013.  Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial.. PloS one. 8(9):e75665. Abstract
Gilbert PB, Excler J-L, Tomaras GD, Carpp LN, Haynes BF, Liao H-X, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al..  2017.  Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.. PloS one. 12(5):e0176428. Abstract
E
Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, Decamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M et al..  2015.  Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.. PLoS computational biology. 11(2):e1003973. Abstract
D
Dommaraju K, Kijak G, Carlson JM, Larsen BB, Tovanabutra S, Geraghty DE, Deng W, Maust BS, Edlefsen PT, Sanders-Buell E et al..  2014.  CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.. PloS one. 9(10):e111334. Abstract
B
Bonsignori M, Pollara J, Moody AM, Alpert MD, Chen X, Hwang K-K, Gilbert PB, Huang Y, Gurley TC, Kozink DM et al..  2012.  Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family.. Journal of virology. 86(21):11521-32. Abstract
A
Astronomo RD, Santra S, Ballweber-Fleming L, Westerberg KG, Mach L, Hensley-McBain T, Sutherland L, Mildenberg B, Morton G, Yates NL et al..  2016.  Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.. EBioMedicine. 14:97-111. Abstract